Physician profile
Carol A Traphagan
NPI 1326152448
$2,933.75
in general payments reported to CMS, 2019-2025
19 companies · $1,042 in 2025
The $1,042 reported for 2025 was more than what 85% of Adult Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $186).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $564 · 2023: $688 · 2024: $640 · 2025: $1,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,369.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $589.33 | 2022-2025 | |
| Pfizer INC. | $422.23 | 2022-2025 | |
| Amgen INC. | $382.14 | 2022-2025 | Repatha, Repatha |
| Abbott Laboratories | $276.07 | 2022-2025 | Cardiomems |
| Novo Nordisk INC | $224.83 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $199.53 | 2022-2025 | Verquvo |
| Cvrx, INC. | $198.84 | 2024-2025 | Barostim Neo System |
| Medtronic, INC. | $172.35 | 2022-2023 | Micra |
| Edwards Lifesciences Corporation | $127.70 | 2025 | Sapien 3 Ultra Resilia |
| Lexicon Pharmaceuticals, INC. | $67.74 | 2024 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $53.72 | 2022-2024 | Farxiga |
| Alnylam Pharmaceuticals INC. | $42.71 | 2023 | Onpattro |
| Regeneron Healthcare Solutions, INC. | $34.19 | 2024-2025 | Evkeeza |
| Boston Scientific Corporation | $33.12 | 2023 | Lux-Dx Insertable Cardiac Monitor, Emblem Mri S-Icd |
| E.R. Squibb & Sons, L.L.C. | $30.98 | 2023-2025 | Eliquis |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $30.06 | 2023 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $18.31 | 2025 | |
| Bridgebio Pharma, INC. | $15.21 | 2025 | Attruby |
| Janssen Pharmaceuticals, INC | $14.69 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Traphagan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.